NL2033322B1 - Baicalin-calcium alginate thermosensitive nanogel as well as preparation method and application thereof - Google Patents
Baicalin-calcium alginate thermosensitive nanogel as well as preparation method and application thereof Download PDFInfo
- Publication number
- NL2033322B1 NL2033322B1 NL2033322A NL2033322A NL2033322B1 NL 2033322 B1 NL2033322 B1 NL 2033322B1 NL 2033322 A NL2033322 A NL 2033322A NL 2033322 A NL2033322 A NL 2033322A NL 2033322 B1 NL2033322 B1 NL 2033322B1
- Authority
- NL
- Netherlands
- Prior art keywords
- baicalin
- nanogel
- calcium alginate
- thermosensitive
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Manufacturing & Machinery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (5)
1. Werkwijze voor het bereiden van thermogevoelige nanogel van baicalin-calciumalginaat, waarbij de thermogevoelige nanogel van baicalin-calciumalginaat wordt bereid uit een actief farmaceutisch ingrediënt baicalin en farmaceutisch effectieve hulpmaterialen, waarbij de werkwijze specifiek de volgende stappen omvat: {1} bereiding van nanogel van baicalin-calciumalginaat het toevoegen van respectievelijk vloeibare paraffine, Span 80 en Tween 80 in een gewichtsverhouding van (500 tot 200):{5 tot 1,5):1, en het volledig dispergeren van het mengsel in een water- bad bij 40 tot 60°C en 500 rpm als een oliefase; het instellen van een roersnelheid op 1000 rpm en het druppelen van 60 tot 300 delen natriumalginaatoplossing die baicaline bevat in de oliefase met een stroomsnelheid van 0,75 ml/min; na voltooiing van het druppe- len, de gemengde oplossing continu roeren totdat de waterfase grondig is gemengd met de oliefase; het toevoegen van 20 tot 100 delen verharder met een stroomsnelheid van 0,25 ml/min onder roe- ren met een snelheid van 1000 rpm; na voltooiing van het druppe- len, het mengsel gedurende 1 uur continu roeren, de resulterende nanogel 15 minuten bij 3.000 rpm centrifugeren, de waterfase af- scheiden om een suspensie van nanogel van baicalin-calciumalginaat te verkrijgen, en snel invriezen met vloeibare stikstof en vries- drogen van de suspensie van nanogel van baicalin-calciumalginaat; waarbij in de natriumalginaatoplossing die baicalin bevat, een na- triumalginaatconcentratie 1 tot 10 mg/ml is, een baicalinconcen- tratie 0,1 tot 20 mg/ml is en de verharder een 70% ethanoloplos- sing van 0,5 tot 5 mg/ml calcium chloride is; (2) bereiding van thermogevoelige nancgel van baicalin- calciumalginaat het toevoegen van normaal zoutoplossing aan 6 gewichtsdelen van nanogel van baicalin-calciumalginaat bereid in S1, het gelijk- matig dispergeren van de nanogel, het toevoegen van 1 gewichtsdeel poloxameer 188 (P 188) en 7 gewichtsdelen poloxameer 407 (P 407) onder ijsbadconditie, en het mengen van het mengsel totdat alle materialen gelijkmatig zijn opgelost om thermogevoelige nanogel van baicalin-calciumalginaat te verkrijgen.
2. Werkwijze voor het bereiden van thermogevoelige nanogel van baicalin-calciumalginaat volgens conclusie 1, waarbij de baicalin- calciumalginaat thermogevoelige nanogel gelatineachtig is bij 30 + 2 °C.
3. Werkwijze voor het bereiden van thermogevoelige nanogel van baicalin-calciumalginaat volgens conclusie 1, waarbij een ge- wichtsverhouding van de vloeibare paraffine tot de Span 80 tot de Tween 80 333,33:2,33:1 is; de hoeveelheid van de natriumalginaat- oplossing die baicaline bevat 100 gewichtsdelen is en de hoeveel- heid verharder 33,33 gewichtsdelen is.
4. Thermogevoelige nanogel van baicalin-calciumalginaat bereid door de bereidingswerkwijze volgens een van de conclusies 1 tot 3.
5. Toepassing van de warmtegevoelige nanogel van baicalin- calciumalginaat volgens conclusie 4 bij het bereiden van een ge- neesmiddel voor de behandeling van een beroerte.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111247965.7A CN113750039B (zh) | 2021-10-26 | 2021-10-26 | 一种黄芩苷-海藻酸钙温敏纳米凝胶、制备方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
NL2033322A NL2033322A (en) | 2023-05-19 |
NL2033322B1 true NL2033322B1 (en) | 2023-06-21 |
Family
ID=78784429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL2033322A NL2033322B1 (en) | 2021-10-26 | 2022-10-14 | Baicalin-calcium alginate thermosensitive nanogel as well as preparation method and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN113750039B (nl) |
NL (1) | NL2033322B1 (nl) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1127572A3 (en) * | 2000-02-25 | 2003-05-02 | Basf Aktiengesellschaft | Use of flavones for treating cycloxygenase-2 mediated diseases |
CN100554417C (zh) * | 2007-12-19 | 2009-10-28 | 天津大学 | 海藻酸-碳酸钙杂化凝胶固定β-葡萄糖醛酸苷酶的方法 |
CN101732237A (zh) * | 2010-01-12 | 2010-06-16 | 中国人民武装警察部队医学院 | 一种黄芩苷温敏凝胶及制备方法和用途 |
CN102349944B (zh) * | 2010-06-01 | 2014-05-07 | 四川大千药业有限公司 | 一种黄芩提取物鼻用温敏型原位凝胶及其制备方法和用途 |
CN103655482B (zh) * | 2012-09-19 | 2016-05-25 | 重庆医科大学 | 用于载药的自微乳化海藻酸钙凝胶微丸及其制备方法 |
LT3494125T (lt) * | 2016-08-02 | 2022-11-10 | Virginia Commonwealth University | Kompozicijos, apimančios 5-cholesteną-3, 25-diolį, 3-sulfatą (25hc3s) arba farmaciniu požiūriu priimtiną jo druską ir bent vieną ciklinį oligosacharidą |
CN108078915A (zh) * | 2018-01-12 | 2018-05-29 | 河北科技大学 | 一种鼻腔给药用温敏原位凝胶 |
CN111434340B (zh) * | 2019-01-11 | 2022-04-12 | 天津中医药大学 | 一种温敏凝胶剂及其制备方法 |
-
2021
- 2021-10-26 CN CN202111247965.7A patent/CN113750039B/zh active Active
-
2022
- 2022-10-14 NL NL2033322A patent/NL2033322B1/en active
Also Published As
Publication number | Publication date |
---|---|
CN113750039A (zh) | 2021-12-07 |
CN113750039B (zh) | 2023-08-18 |
NL2033322A (en) | 2023-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6298460B2 (ja) | プロゲステロン製剤 | |
CN101066260B (zh) | 一种辅酶q10乳剂及其冻干乳剂及制备方法 | |
BRPI0506812B1 (pt) | composição base anidra auto-microemulsificável, microemulsão e método de preparação da composição base automicroemulsificável | |
ES2222581T3 (es) | Preparaciones de medicinas para tratar disfuncion sexual. | |
WO1997020555A1 (en) | Treatment or prevention of anoxic or ischemic brain injury with melatonin-containing compositions | |
TW201818946A (zh) | 包含至少一種氧化膽固醇硫酸鹽及至少一種聚烯烴二醇、羧甲基纖維素及聚氧甘油酯之組成物及彼等之使用方法 | |
CN108904522A (zh) | 一种肝素衍生物-泊洛沙姆温敏型水凝胶及其制备方法 | |
CN101336890A (zh) | 一种抗癌缓释凝胶注射剂 | |
KR101175163B1 (ko) | 이소소르비드함유 젤리제제 | |
WO2011047637A1 (zh) | 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法 | |
NL2033322B1 (en) | Baicalin-calcium alginate thermosensitive nanogel as well as preparation method and application thereof | |
CN103816120B (zh) | 含有维生素k1的脂肪乳剂 | |
CN102670484B (zh) | 甘露糖修饰的固体脂质纳米粒复合凝胶及其制备方法 | |
CN105919949A (zh) | 一种稳定的氟比洛芬酯冻干乳及其制备方法 | |
CN103505414B (zh) | 丁苯酞滴鼻剂及其制备方法 | |
CN110123757B (zh) | 一种应用于治疗脉管异常的乙醇泡沫硬化剂及制备方法 | |
CN1092646A (zh) | 含有效成分的冻干乳液 | |
WO2022193975A1 (zh) | 供注射用罗哌卡因长效溶液制剂及其制备方法 | |
WO2009135432A1 (zh) | 丹酚酸b的抗血栓应用 | |
CN109528632A (zh) | 尼莫地平药物组合物、尼莫地平注射液及其制备方法 | |
CN108210929A (zh) | 一种含有依托考昔的药物组合物及其制备方法 | |
WO2016119114A1 (zh) | 一种葛根素纳米晶胶囊剂及其制备方法 | |
PT1232746E (pt) | Composição farmacêutica que compreende goma xantana | |
RU2705723C1 (ru) | Суппозитории ректальные с эритропоэтином, обладающие репаративной и антиоксидантной активностью | |
CN105796497A (zh) | 一种高贮藏稳定性薏苡仁油温敏脂质体的制备方法 |